\
&
Contact us
\
&
Contact us
Published on | 3 years ago
ProgrammesThere is 1 attachment connected to this article.
Attachments are only accessible for people with an account on the NCP Flanders website.
NCP Flanders has prepared a video series and accompanying slide deck which takes stakeholders through the basics of proposal writing under Pillar II of the Horizon Europe programme with focus on Research and Innovation Actions (RIA) & Innovation Actions (IA). You can find the video series under the video section of our website here. The materials are intended for personal use and viewing only. Please don't copy or circulate without asking permission.
Another tool that could be helpful when preparing a proposal under Pillar II (RIA or IA) is the recently published annotated proposal template, prepared by the NCP network BRIDGE2HE. You can find this annotated template in attachment or on our website here (under documents). This document contains recommendations by NCPs and expert evaluators.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
